옵션 체인은 다양한 행사가격과 만기일에 대한 Arbutus Biopharma의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Arbutus Biopharma에 대한 시장 심리를 평가합니다..

Arbutus Biopharma (NASDAQ:ABUS) 주식, 옵션 체인

Arbutus Biopharma

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Health Care

Legal

ABUS

MRNA

수요일 4월 3일, Arbutus Biopharma(NASDAQ:ABUS)의 주식은 회사가 법정에서 Moderna Inc(NASDAQ:MRNA)에 대한 소송을 제기할 권한을 부여받은 후 20% 이상 급등했다.



What Happened: Arbutus는 첫 소송에서 Moderna에 대해 클레임을 제기하는데 성공했는 데, 이 소송의 내용은 Moderna가 개발한 코로나 백신의 기반이 된

아르부투스 주식, 모더나와의 코로나 백신 특허 쟁송을 앞두고 급등

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

Stifel analyst J. Bruce Chan maintains Forward Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) with a Hold and raises the price target from $34 to $36.

News

Price Target

Analyst Ratings

FWRD

Stifel Maintains Hold on Forward Air, Raises Price Target to $36

LSI Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) shares are trading higher after the <a href="https://www.benzinga.com/pressreleases/25/01/b43155795/lsi-industries-reports-fiscal-2025-second-quarter-results-and-declares-quarterly-cash-dividend">second-quarter earnings result</a>.
The company reported second-quarter sales growth of 36% year-on-year to $147.734 million, beating the analyst consensus estimate of $129.195 million.
The increase was driven by broad-based demand strength across its vertical markets. The company also benefitted from solid organic growth within the Display Solutions segment, along with contributions from the EMI acquisition completed in April 2024.
Gross profit rose 10.5% at $34.86 million and the margin decreased by 530 basis points to 23.6%.
The operating income for the quarter grew 8.2% to $8.45 million and the operating margin of 5.7% contracted by 150 basis points.
The Company generated adjusted EBITDA of $13.3 million or 9.0% of net sales, an increase of more than 20% versus the year-ago period.&nbsp;
Adjusted EPS of $0.26<a href="https://www.benzinga.com/earnings"> beat the consensus estimate of $0.20.</a>
The operating cash flow was $9.89 million. Free cash flow for the quarter totaled $8.8 million.
The Company declared a regular cash dividend of $0.05 per share payable on February 11, 2025, to shareholders of record on February 3, 2025.
&#8220;LSI delivered 14% organic sales growth in the fiscal second quarter, supported by strong demand across our core refueling, c-store, and grocery verticals,&#8221; stated President and CEO James A. Clark.
Looking ahead, the company said it remains well positioned to drive continued, profitable growth entering the <a href="https://www.benzinga.com/calendars/guidance">second half of fiscal year 2025.</a>
Price Action: LYTS shares are trading higher by 20.6% at $23.85 on the last check Thursday.
Photo via Shutterstock.

Earnings

Equities

Guidance

Movers

General

LYTS

LSI Industries Q2 Sales Surge As Demand Across Verticals Strengthen; Stock Skyrockets

DA Davidson analyst Peter Winter maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Neutral and raises the price target from $49 to $50.

FITB

DA Davidson Maintains Neutral on Fifth Third Bancorp, Raises Price Target to $50

Stifel analyst J. Bruce Chan maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Buy and lowers the price target from $368 to $364.

Stifel Maintains Buy on FedEx, Lowers Price Target to $364

Stifel analyst J. Bruce Chan maintains Expeditors Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) with a Hold and lowers the price target from $122 to $117.

EXPD

Stifel Maintains Hold on Expeditors Intl, Lowers Price Target to $117

DA Davidson analyst Peter Winter maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Neutral and lowers the price target from $71 to $67.

DA Davidson Maintains Neutral on Comerica, Lowers Price Target to $67

COLAU

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

&ldquo;<a href="https://www.benzinga.com/cannabis">Cannabis</a> is probably the greatest medicine on the planet that everybody can have,&rdquo; says Whoopi Goldberg as she phones in from her home, her cat comfortably nestled on her lap. The actress, comedian, and entrepreneur speaks passionately about her long-standing relationship with cannabis, reflecting on its dual benefits as both a pain reliever and a source of joy. &ldquo;For people like me, it was always used to stop the [menstrual] cramps &ndash; and the side hustle of that is that it was fun, it made you laugh and stuff,&rdquo; she adds.
Goldberg is an advocate of medicine that feels good. Why should medicating feel uncomfortable? Why does it have to feel like a hard pill to swallow &ndash; literally? &ldquo;We know that&#39;s wrong. And people say, &lsquo;Well, that&#39;s just anecdotal.&rsquo; But it&#39;s not anecdotal. Everybody you talk to would tell you that medicine doesn&#39;t have to be horrifying. Especially when it&#39;s herbal, when it&#39;s growing out of the ground and doesn&#39;t need an additive, which means it can stay reasonably priced for people to go pick it up,&rdquo; she voices.
<h3>All In The Family</h3>
Goldberg&rsquo;s relationship with cannabis is deeply personal and family-driven. Her latest venture, Emma &amp; Clyde, encapsulates this connection. &ldquo;Emma &amp; Clyde is named after my family because my mother used cannabis for medicinal purposes. And my brother liked the recreational. They are two people that represent weed as it stands in the real world,&rdquo; she explains. This brand, under the WhoopFam umbrella, aims to provide high-quality products for both medicinal and recreational users.
<img alt="Whoopi and her mother, Emma" src="https://imageio.forbes.com/specials-images/imageserve/667c61f3bf384aa461af5fb1/Whoopi-and-her-mother--Emma/960x0.jpg?format=jpg&amp;width=1440" style="height:575px; width:624px" />
Whoopi and her mother, Emma - Courtesy of WhoopFam
Her journey with the plant began long before it became a business venture. &ldquo;I&#39;m not sure when everybody in my family got on board. I didn&#39;t realize that my mother had been utilizing it for herself until after she passed away,&rdquo; Goldberg reveals, adding a poignant layer to her advocacy.
She also reflects on her early experiences with cannabis, recounting how she and her brother would smoke in the days when the plant was still taboo. &ldquo;My brother and I used to smoke in the days when it was just something that you could do under the tree in the backyard when nobody could see you. And I know that he would love this idea that you can go and get what you need medicinally. You can go and get what you need recreationally,&rdquo; she recounts. This early exposure laid the groundwork for her later advocacy and business ventures, which are not just focused on creating products but also on challenging societal norms and pushing for broader acceptance and legalization of cannabis.
<img alt="Whoopi and her brother, Clyde" src="https://imageio.forbes.com/specials-images/imageserve/667c62150858919ba3c8a24b/Whoopi-and-her-brother--Clyde/960x0.jpg?format=jpg&amp;width=1440" style="height:450px; width:360px" />
Whoopi and her brother, Clyde
&ldquo;Medicine should be in the hands of people,&rdquo; she asserts. Her mission is clear: to demystify cannabis and make it a readily available option for those who need it.
Keeping things within her close circle of friends and family, Goldberg has once again decided to partner with Maya Elisabeth, co-creator of the original Whoopi &amp; Maya brand. The choice was driven by the exceptional quality of their initial collaboration. &ldquo;We made a great product. Whoopi &amp; Maya was great. We were out there first and before many, many other people. So far, I haven&rsquo;t found anything as good as what we created back then,&rdquo; she says.
<h2>Stop The Pain</h2>
Goldberg&rsquo;s defense of medicinal cannabis use is deeply personal, particularly for managing menstrual pain. &ldquo;My premier reason for utilizing cannabis always was for making sure I could stop the pain,&rdquo; she shares, drawing from her own experience with debilitating cramps.
Her close friends also played a major role, as several of them were cancer patients medicating with cannabis. &ldquo;We always made sure in our circle that we had enough for everyone, for whatever reason it was. And, you know, you used to be able to go buy a dime bag this big [spreads her arms] for $10, and you&rsquo;d take out all the stems and seeds, and you would try to plant the seeds hoping something would grow&hellip; But you always knew it wouldn&#39;t.&rdquo;
As Goldberg goes on to reflect on the road traveled, from the $10 bag days to the current landscape of legality and sophisticated cannabis products, her tone is one of fascination. &ldquo;For me, it is an honor because I think it&#39;s probably the greatest medicine on the planet,&rdquo; she repeats. &ldquo;You don&#39;t have to mix it with things you can&#39;t pronounce. It is what it is: it is clean, it is strong, and you can regulate how much strength you need depending on what you&#39;re doing with the plant.&rdquo;
Addressing the parallels between the taboos surrounding women&rsquo;s health issues and the stigma associated with cannabis use, Goldberg responds emphatically that the stigma is dissipating. &ldquo;They&#39;re not taboo anymore because we all know women get a period. We know. So you can either make it hard, which they&#39;ve done in terms of creating something that helps women... But this [cannabis] we know works,&rdquo; she asserts.
She acknowledges that while cannabis may not be for everyone, it offers a great alternative for those it does help. &ldquo;Everybody can&#39;t do it. Everybody doesn&#39;t do it. But for those who can, this is a great thing. Some people want to take a Midol or they want to take any of the other things that are out there. And, you know, maybe it works for them. It didn&#39;t work for me. Cannabis works for me,&rdquo; she explains.
Consequently, Goldberg recommends people explore the various benefits of cannabis. &ldquo;I encourage people who are looking for something that gets rid of pain, that makes you less anxious. There are all kinds of things that this particular plant can do, and I suggest people look into all those things and know that what makes it affordable is that it&#39;s grown out of the ground by regular, normal people, and you can&#39;t lace it with anything. You can&#39;t mix it with anything because it doesn&#39;t take it; it doesn&#39;t want to be mixed with anything. Either roll it up or crush it up. Put it in some hot water, make a tea, whatever you want to do, but try it and see if it works for you. For me, it removes a lot of pain issues.&rdquo;
Goldberg&rsquo;s perspective resonates with the experiences of other celebrities who advocate for cannabis use in managing women&rsquo;s health issues. In a recent Forbes interview,&nbsp;<a href="https://www.forbes.com/sites/javierhasse/2024/05/01/i-chose-weed-over-drugs-tiffany-haddish-calls-for-cannabis-legalization-for-womens-health-talks-berner-collab/" target="_self" title="https://www.forbes.com/sites/javierhasse/2024/05/01/i-chose-weed-over-drugs-tiffany-haddish-calls-for-cannabis-legalization-for-womens-health-talks-berner-collab/">Tiffany Haddish</a>&nbsp;shared her struggles with endometriosis and how cannabis has been a vital tool for&nbsp;<a href="https://www.forbes.com/health/healthy-aging/best-tools-for-chronic-pain/" target="_self">coping with chronic pain</a>. Haddish&#39;s candid revelations echo Goldberg&#39;s sentiments about the necessity of considering cannabis as an effective tool to manage women&rsquo;s health issues.
Scientific studies support Goldberg&rsquo;s claims about the efficacy of cannabis in treating menstrual pain. Research published in the&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693518/" rel="nofollow noopener noreferrer" target="_blank" title="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693518/">Journal of Obstetrics and Gynaecology Canada</a>&nbsp;found that cannabis significantly reduced pain and improved sleep and nausea for women suffering from endometriosis. Another study in the&nbsp;<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671947/" rel="nofollow noopener noreferrer" target="_blank" title="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671947/">Journal of Clinical Medicine</a>&nbsp;revealed that cannabinoids interact with the endocannabinoid system to alleviate symptoms, offering a promising alternative to traditional pain medications.
In the United States, the menstrual cramp treatment market is substantial, with millions of women seeking relief from pain each year. The global market for menstrual pain treatments was&nbsp;<a href="https://www.futuremarketinsights.com/reports/dysmenorrhea-treatment-market" rel="nofollow noopener noreferrer" target="_blank" title="https://www.futuremarketinsights.com/reports/dysmenorrhea-treatment-market">valued</a>&nbsp;at almost $6 billion in 2022, and it continues to grow as more women seek effective and natural remedies. Goldberg&rsquo;s commitment to this cause is not only personal but also addresses a significant and often overlooked market need.
<h2>&lsquo;We Never Left&rsquo;</h2>
<img alt="EMMA &amp; CLYDE Logo" src="https://imageio.forbes.com/specials-images/imageserve/667c85b0d8e0ef6456aade46/EMMA---CLYDE-Logo/960x0.jpg?format=jpg&amp;width=1440" style="height:450px; width:354px" />
EMMA &amp; CLYDE Logo - Courtesy of WhoopFam
In discussing the restructuring of her business and the creation of WhoopFam, Goldberg highlights a family-oriented approach. &ldquo;We&#39;ve not actually left the cannabis game, but we&#39;ve had to sort of restructure things. And once we figured out that that&#39;s what we wanted to do, we then went ahead and we approached Maya and went also and created the new products, which is that Emma &amp; Clyde, which are named after my mother and brother and, created a family umbrella which is called the WhoopFam. So we all put different things under our umbrella; other people&#39;s products... We&#39;ll take ideas from people and create stuff, simultaneously with them. So it&#39;s really nice,&rdquo; she explains.
The actress and businesswoman also addresses the need for supportive laws and banking reforms to help entrepreneurs, especially people of color, succeed in the cannabis industry. &ldquo;Once we&#39;re able to get people to stop talking about it negatively&hellip; There&#39;s a lot of stuff that&#39;s bad and we shouldn&#39;t be doing it, but it&#39;s perfectly legal out there. This [cannabis], I want to make sure it gets away from being classified incorrectly so that all the people they say they want to help, mostly black and brown people, the ones who went to jail, can have a shot in this business.&rdquo;
She continues, &quot;And now we are taking them out of jail and we want to give them the licenses. Well, not only do you have to give them the licenses, but you have to change the banking laws so they can have a shot at making it. Because, right now, it&#39;s impossible.&quot;
Goldberg emphasizes the importance of realistic support. &quot;I know that people have the best ideas in mind at heart. But let&#39;s be realistic: If you&#39;re going to do that, you have to help people succeed, not put more things in their way. And this banking thing is a problem,&rdquo; she ends.
As she continues to champion cannabis and its myriad benefits, Goldberg&rsquo;s story serves as a powerful reminder of the plant&rsquo;s potential to heal, bring joy, and drive social change. Stay tuned for more updates on Emma &amp; Clyde.
Follow me on&nbsp;<a href="https://www.twitter.com/javierhasse" rel="nofollow noopener noreferrer" target="_blank">Twitter</a>&nbsp;or&nbsp;<a href="https://www.linkedin.com/in/javierhasse/" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a>.&nbsp;Check out&nbsp;my&nbsp;<a href="https://elplanteo.com/" rel="nofollow noopener noreferrer" target="_blank">website</a>&nbsp;or&nbsp;some of my other work&nbsp;<a href="https://benzinga.com/cannabis" rel="nofollow noopener noreferrer" target="_blank">here</a>.&nbsp;
This article was originally published on <a href="https://www.forbes.com/sites/javierhasse/2024/06/26/whoopi-goldberg-talks-cannabis-medicine-doesnt-have-to-be-horrifying-or-unreasonably-priced/">Forbes</a> on June 26, 2024, and appears here with permission. It is an external, unpaid contribution. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.
Images courtesy of WhoopFam. Cover image edited by Javier Hasse.

Cannabis

Markets

Interview

Whoopi Goldberg Talks Cannabis: The Planet's 'Greatest Medicine... Pain Reliever And Source Of Joy'

Freeport-McMoran Chairman Richard Adkerson Says Company Will Support New Presidents In U.S. And Indonesia 'As We Do In All Countries Where We Operate'; 'Confident' Will Find Common Ground With Indonesian Government On Extending Operating License Beyond 2041

JMP Securities analyst Chris Muller reiterates Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Market Outperform and maintains $14 price target.

Reiteration

JMP Securities Reiterates Market Outperform on Two Harbors Inv, Maintains $14 Price Target

Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) will release earnings results for its fourth quarter, after the <a href="https://www.benzinga.com/quote/TXN/earnings">closing bell on Thursday, Jan. 23, 2025.</a>
Analysts expect the Dallas, Texas-based company to report quarterly earnings at $1.2 per share, down from $1.49 per share in the year-ago period. Texas Instruments projects to report revenue of $3.87 billion for the recent quarter, compared to $4.08 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 16, the company's board of directors declared a quarterly cash dividend of $1.36 per share of common stock.
Texas Instruments shares gained 0.9% to close at $197.05 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TXN/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Rosenblatt analyst Hans Mosesmann maintained a Buy rating with a price target of $250 on Jan. 21, 2025. This analyst has an accuracy rate of 83%.</li>
<li>B of A Securities analyst Vivek Arya maintained a Neutral rating and cut the price target from $220 to $215 on Oct. 23, 2024. This analyst has an accuracy rate of 81%.</li>
<li>Truist Securities analyst William Stein maintained a Hold rating and cut the price target from $198 to $190 on Oct. 23, 2024. This analyst has an accuracy rate of 85%.</li>
<li>Cantor Fitzgerald analyst C J Muse reiterated a Neutral rating with a price target of $200 on Oct. 23, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Barclays analyst Blayne Curtis maintained an Equal-Weight rating and cut the price target from $210 to $200 on Oct. 23, 2024. This analyst has an accuracy rate of 76%.</li>
</ul>
Considering buying TXN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23025947/image-160-1024x522.png" alt="" class="wp-image-746254" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23025947/image-160-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23025947/image-160-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23025947/image-160-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23025947/image-160.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Trading Ideas

Texas Instruments Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Crypto
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43153205/bets-favoring-dogecoin-etf-approval-in-2025-jump-after-bitwises-delaware-filing-top-trader-paints-over-4000-upside-for-memecoin">Bets Favoring Dogecoin ETF Approval In 2025 Jump After Bitwise&#8217;s Delaware Filing—Top Trader Paints Over 4000% Upside For Memecoin</a></li>
<li><a href="https://www.benzinga.com/25/01/43152664/trump-memecoin-reached-a-market-valuation-within-two-days-that-took-jeff-bezos-amazon-more-than-13-years">Trump Memecoin Achieved This Valuation Milestone Inside Two Days That Took Jeff Bezos&#8217; Amazon Over 13 Years</a></li>
<li><a href="https://www.benzinga.com/25/01/43151055/sam-altman-founded-world-network-rallies-on-openais-role-in-ai-project-stargate">Sam Altman-Founded Worldcoin Network Rallies, Defying Bitcoin and Ethereum Decline, Amid OpenAI&#8217;s Role in Project Stargate</a></li>
<li><a href="https://www.benzinga.com/25/01/43150952/blackrock-ceo-larry-fink-says-bitcoin-could-rise-to-700000-on-monetary-debasement-political-instability-fears">Blackrock CEO Larry Fink Says Bitcoin Could Rise To $700,000 On Fiat Fears: &#8216;If You&#8217;re Frightened Of The Debasement</a>…&#8217;</li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43150757/bitcoin-ethereum-dogecoin-drop-amid-stock-rally-cooling-investor-sentiment-on-trump-analyst-projects-btc-at-150k-if-history-repeats">Bitcoin, Ethereum, Dogecoin Drop Amid Stock Rally, Cooling Investor Sentiment On Trump: Analyst Projects BTC At $150K If History</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43159152/bitcoin-at-102000-but-why-does-the-market-feel-so-bearish">Bitcoin At $102,000 But Why Does The Market Feel So Bearish?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43158022/solana-jumps-20-in-7-days-why-is-sol-going-up">Solana Jumps 20% In 7 Days: Why Is SOL Going Up?</a></li>
<li><a href="https://www.benzinga.com/25/01/43156012/evaa-protocol-secures-25m-in-private-token-sale-to-expand-ton-defi-embargo-ends-at-12pm-cet">EVAA Protocol Secures $2.5M In Private Token Sale To Expand TON DeFi</a></li>
</ul>
US Markets­­­­­­­­
<ul>
<li><a href="https://www.benzinga.com/25/01/43152748/sp-500-hits-new-record-fear-among-us-investors-eases-but-fear-greed-index-remains-in-fear-zone">S&amp;P 500 Hits New Record As Netflix Reports Strong Results: Investor Sentiment Improves But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>
US Politics
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43152917/elon-musk-led-doge-targets-us-penny-over-179m-annual-production-cost">Elon Musk&#8217;s DOGE Takes Aim At The US Penny Citing Soaring Production Costs</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li><a href="https://www.benzinga.com/25/01/43156951/billionaire-richard-branson-criticizes-trumps-decision-to-withdraw-from-paris-climate-deal-powering-the-world-with-clean-energy-is-common-sense">Billionaire Richard Branson Criticizes Trump&#8217;s Decision To Withdraw From Paris Climate Deal: &#8216;Powering The World With Clean Energy Is Common Sense&#8217;</a></li>
</ul>
World Politics
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43156850/wto-chief-says-everyone-will-pay-if-tit-for-tat-trade-war-breaks-out-amid-trumps-tariff-threat-leading-to-double-digit-global-gdp-losses">WTO Chief Says &#8216;Everyone Will Pay&#8217; If &#8216;Tit-For-Tat&#8217; Trade War Breaks Out Amid Trump&#8217;s Tariff Threat, Leading To Double-Digit Global GDP Losses</a></li>
</ul>
World Economy
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/01/43156258/asia-and-europe-markets-mixed-dollar-index-ticks-lower-global-markets-today-while-us-slept">Asia And Europe Markets Mixed; Dollar Index Ticks Lower &#8211; Global Markets Today While US Slept</a></li>
</ul>
Tech
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43155074/samsung-teases-galaxy-s25-edge-to-take-on-apples-rumored-iphone-17-air">Samsung Teases Galaxy S25 Edge, To Take On Apple&#8217;s Rumored iPhone 17 Air</a></li>
<li><a href="https://www.benzinga.com/news/global/25/01/43153555/tiktok-parent-bytedance-plans-12-billion-ai-chip-investment-in-2025-to-bolster-global-ai-ambitions-amid-us-export-controls-report">TikTok-Parent ByteDance Plans $12 Billion AI Chip Investment In 2025 To Bolster Global AI Ambitions Amid US Export Controls: Report</a></li>
<li><a href="https://www.benzinga.com/25/01/43152356/linkedin-hit-with-lawsuit-for-violating-user-privacy-allegedly-sharing-private-data-for-ai-model-training">Microsoft&#8217;s LinkedIn Hit With Lawsuit For Violating User Privacy, Allegedly Sharing Private Data For AI Model Training</a></li>
<li><a href="https://www.benzinga.com/25/01/43151196/samsung-google-team-up-to-develop-ar-glasses-entering-the-race-against-meta-and-apple">Samsung, Google Team Up On AR Glasses Development, Duo To Enter Race Against Meta And Apple</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43150793/nvidia-supplier-sk-hynix-soars-102-in-revenue-but-stock-slides-310-despite-ai-memory-boom">Nvidia Supplier SK Hynix Soars 102% In Revenue, But Stock Drops Despite AI Memory Boom</a></li>
<li><a href="https://www.benzinga.com/25/01/43160342/metas-pay-or-consent-policy-faces-fresh-criticism-from-eu-consumer-group">Meta&#8217;s Pay-Or-Consent Policy Faces Fresh Criticism From EU Consumer Group</a></li>
<li><a href="https://www.benzinga.com/25/01/43159614/tal-education-posts-62-jump-in-q3-sales-driven-by-ai-learning-devices">TAL Education Posts 62% Jump In Q3 Sales Driven By AI Learning Devices; Stock Surges</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43159015/whats-going-on-with-d-wave-quantum-stock-today-2">What&#8217;s Going On With D-Wave Quantum Stock Today?</a></li>
<li><a href="https://www.benzinga.com/news/contracts/25/01/43158558/ses-secures-10m-in-ai-powered-battery-contracts-stock-jumps">SES Secures ~$10M In AI-Powered Battery Contracts; Stock Jumps</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/43157791/these-analysts-cut-their-forecasts-on-electronic-arts-after-preliminary-q3-results">These Analysts Cut Their Forecasts On Electronic Arts After Preliminary Q3 Results</a></li>
</ul>
Electric Vehicle
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43155095/gm-recalls-nearly-3000-chevrolet-equinox-evs-over-adaptive-cruise-control-glitch">GM Recalls Nearly 3,000 Chevrolet Equinox EVs Over Adaptive Cruise Control Glitch</a></li>
<li><a href="https://www.benzinga.com/tech/25/01/43155064/polestar-ceo-looks-to-attract-tesla-customers-disenchanted-by-elon-musks-politics-somebody-outside-of-germany-endorsing-right-wing-politicial-parties-totally-unacceptable">Polestar CEO Looks To Attract Tesla Customers Disenchanted By Elon Musk&#8217;s Politics: &#8216;Somebody Outside Of Germany Endorsing Right-Wing Politicial Parties&#8230; Totally Unacceptable&#8217;</a></li>
<li><a href="https://www.benzinga.com/25/01/43152718/tesla-to-have-a-choppy-first-half-owing-to-new-ev-policies-deliveries-and-margins-however-this-analyst-expect-over-20-upside-from-current-level-with-a-500-target-price">Tesla Set For A &#8216;Choppy&#8217; First Half Amid New EV Policies, But This Analyst Sees 20% Upside For Elon Musk&#8217;s EV Company With A $500 Price Target</a></li>
<li><a href="https://www.benzinga.com/25/01/43151994/tesla-to-hike-car-prices-in-canada-by-as-much-as-c9000">Tesla To Raise Prices In Canada: Model 3 Sees Up To $6,200 Hike</a></li>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43150976/dan-ives-raises-tesla-price-target-to-550-sees-golden-era-for-elon-musk-under-trump-sees-bull-case-upside-of-over-56-if-optimus-robot-counted-in-valuation">Dan Ives Raises Tesla Price Target To $550, Sees &#8216;Golden Era&#8217; For Elon Musk Under Trump, Sees Bull Case Upside Of Over 56% If Optimus Robot Counted In Valuation</a></li>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/43156862/tesla-rivals-rivian-lucid-fall-sharply-after-donald-trump-revokes-bidens-ev-targets-freezes-infra-funding-heres-what-technical-analysis-says">Tesla Rivals Rivian, Lucid Fall Sharply After Donald Trump Revokes Biden&#8217;s EV Targets, Freezes Infra Funding: Here&#8217;s What Technical Analysis Says</a></li>
</ul>
Consumer
<ul>
<li><a href="https://www.benzinga.com/25/01/43158327/mccormick-posts-3-sales-growth-in-q4-as-consumer-demand-rise">McCormick Posts 3% Sales Growth In Q4 As Consumer Demand Rise</a></li>
<li><a href="https://www.benzinga.com/25/01/43156651/puma-sees-growth-in-q4-sales-warns-of-cost-cut-in-2025">PUMA Sees Growth In Q4 Sales, Warns Of Cost Cut In 2025</a></li>
</ul>
Communication
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43152468/cnn-prepares-to-lay-off-hundreds-amid-warner-bros-discoverys-digital-overhaul-and-industry-wide-shift-report">CNN Prepares To Lay Off Hundreds Amid Warner Bros. Discovery&#8217;s Digital Overhaul And Industry-Wide Shift: Report</a></li>
<li><a href="https://www.benzinga.com/25/01/43152345/bmw-uk-exits-elon-musks-x-to-continue-posting-on-instagram-facebook">BMW UK Stops Posting On X, Will Use It Only For Customer Support: To Continue Posting On Instagram, Facebook</a></li>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/43150781/netflix-crushed-q4-thanks-to-sports-squid-game-says-gary-black-analyst-highlights-low-attrition-despite-price-hikes-predicts-stock-upside">Netflix Crushed Q4 Thanks To Sports, Squid Game, Says Gary Black: Analyst Highlights Low Attrition Despite Price Hikes, Predicts Stock Upside</a></li>
<li><a href="https://www.benzinga.com/25/01/43160194/why-ast-spacemobile-shares-are-falling-thursday">Why AST SpaceMobile Shares Are Falling Thursday</a></li>
</ul>
Industrial
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43152599/ge-aerospace-american-airlines-and-3-stocks-to-watch-heading-into-thursday">GE Aerospace, American Airlines And 3 Stocks To Watch Heading Into Thursday</a></li>
<li><a href="https://www.benzinga.com/25/01/43159379/alaska-air-group-q4-revenue-up-7-yy-amid-strong-travel-demand-announces-1-billion-share-buyback-plan">Alaska Air Credits Q4 Revenue Jump To Strong Travel Demand, Confirms $1 Billion Share Buyback Plan</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43159332/american-airlines-q4-earnings-beat-debt-milestone-lackluster-guidance-and-more">American Airlines Q4: Earnings Beat, Debt Milestone, Lackluster Guidance And More</a></li>
<li><a href="https://www.benzinga.com/25/01/43158000/ge-vernova-analysts-boost-their-forecasts-after-strong-q4-results">GE Vernova Analysts Boost Their Forecasts After Strong Q4 Results</a></li>
<li><a href="https://www.benzinga.com/news/buybacks/25/01/43157694/ge-aerospace-q4-earnings-eps-beat-dividend-and-stock-buyback-hike-strong-fy25-outlook-and-more">GE Aerospace Q4 Earnings: EPS Beat, Dividend And Stock Buyback Hike, Strong FY25 Outlook And More</a></li>
<li><a href="https://www.benzinga.com/25/01/43157564/textron-analysts-slash-their-forecasts-after-weak-revenue">Textron Analysts Slash Their Forecasts After Weak Revenue</a></li>
</ul>
Healthcare
<ul>
<li><a href="https://www.benzinga.com/25/01/43152862/mccormick-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">McCormick Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
<li><a href="https://www.benzinga.com/25/01/43159537/elevance-health-clocks-q4-profit-despite-fall-in-medicaid-membership-higher-costs">Elevance Health Posts Q4 Profit Despite Medicaid Drop, Rising Costs; Hikes Dividend 5%</a></li>
</ul>
Financial
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43153522/cathie-wood-sees-trumps-second-term-reviving-ipo-market-unlocking-opportunities-in-biotech-and-ai-sectors">Cathie Wood Sees Trump&#8217;s Second Term Reviving IPO Market, Unlocking Opportunities In Biotech And AI Sectors</a></li>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/01/43160029/tesla-nvidia-etfs-in-the-works-to-tap-rising-interest-in-same-day-stock-options">Tesla, Nvidia ETFs In The Works To Tap Rising Interest In Same-Day Stock Options</a></li>
</ul>
General
<ul>
<li><a href="https://www.benzinga.com/25/01/43153571/openais-sam-altman-flip-flops-on-trump-as-500-billion-stargate-ai-project-is-announced-years-after-praising-reid-hoffman-for-stopping-his-re-election">OpenAI&#8217;s Sam Altman Flip Flops On Trump After $500 Billion Stargate AI Project, Says &#8216;I Wish I Had Done More Of My Own Thinking&#8217;</a></li>
<li><a href="https://www.benzinga.com/25/01/43152627/microsoft-ceo-satya-nadella-stands-firm-after-elon-musk-questions-stargates-100-billion-funding-potential-all-i-know-is-im-good-for-my-80-billion">Satya Nadella Stands Firm After Elon Musk Questions Stargate&#8217;s $100 Billion Funding Potential: &#8216;All I Know Is, I&#8217;m Good For My $80 Billion&#8217;</a></li>
</ul>
Space
<ul>
<li><a href="https://www.benzinga.com/25/01/43153196/spacex-eyes-gigabay-at-florida-by-aug-2026">Elon Musk&#8217;s SpaceX Plans Gigabay Facility In Florida For Starship Assembly</a></li>
</ul>
Energy
<ul>
<li><a href="https://www.benzinga.com/25/01/43159372/tamboran-resources-and-santos-forge-partnership-to-explore-darwin-lng-expansion">Tamboran Resources And Santos Forge Partnership To Explore Darwin LNG Expansion</a></li>
</ul>
Photo by SvetlanaParnikova on Shutterstock

$BTC

$ETH

Bitcoin, Ethereum, And Dogecoin Fall As Stocks Rally And Sentiment Cools; Samsung And Google Join AR Glasses Race; Tesla Faces A Turbulent First Half – Top Headlines While The U.S. Slept

JMP Securities analyst Chris Muller maintains Redwood Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWT#NYSE">RWT</a>) with a Market Outperform and lowers the price target from $9 to $8.

JMP Securities Maintains Market Outperform on Redwood Trust, Lowers Price Target to $8

President Donald Trump is back in the Oval Office, and his Day 1 flurry of executive orders suggests a busy and eventful <a href="https://www.benzinga.com/topic/donald-trump">first 100 days ahead.</a>
JPMorgan analysts Joyce Chang and Amy Ho warn that markets have yet to price in the full impact of Trump's aggressive trade stance, regulatory shake-ups, and expansionist ambitions. 
Investors betting on a repeat of Trump's first term should buckle up—this time, the playbook looks bolder.
<h2 class="wp-block-heading">Tariff Tensions: A Trade War Ahead?</h2>
Trump quickly signaled a renewed focus on trade policy, emphasizing his commitment to overhauling the U.S. trade system in his inauguration speech.
Immediate tariffs didn't make the Day 1 cut, but they're looming. The threat of tariffs on <a href="https://www.benzinga.com/25/01/43103527/mexican-peso-canadian-dollar-slide-as-trump-threatens-25-tariffs-expert-eyes-price-hikes-on-typical-us-breakfast">Mexico</a> and <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">Canada</a>—first floated last November—could become reality as early as Feb. 1. 
JPMorgan warns that Trump's team could be eyeing a gradual escalation strategy, hiking tariffs by 2% to 5% per month. With Stephen Miran, Trump's pick for Council of Economic Advisors chair, advocating for a 20% optimal tariff rate, markets may be underestimating the inflationary shock ahead, the analysts say.
Read Also: <a href="https://www.benzinga.com/news/25/01/43150451/jamie-dimo-supports-trumps-tariffs-if-its-a-little-inflationary-but-its-good-for-national-security-so-be-it">Jamie Dimon Supports Trump&#8217;s Tariffs: &#8216;If It&#8217;s A Little Inflationary, But It&#8217;s Good For National Security, So Be It&#8217;</a>
<h2 class="wp-block-heading">Red Tape Revisited: Deregulation Or Mere Reshuffle?</h2>
While businesses cheered Trump's push for regulatory efficiency, JPMorgan suggests it's more of a reshuffle than an outright deregulation spree. 
Basel III reforms and non-bank regulations aren't likely to advance, but the analysts expect faster approvals for M&amp;A deals. Trump's renewed exit from the Paris Agreement reflects his administration's focus on reducing climate-related capital constraints, according to the analysts.
But with a Republican-led Congress still facing hurdles on tax reform, any sweeping economic overhaul remains a tough sell.
<h2 class="wp-block-heading">America First-And Maybe A Bit Bigger?</h2>
Foreign policy under Trump 2.0 appears to focus on economic assertiveness and strategic territorial considerations.
JPMorgan highlights his focus on Mexico, <a href="https://www.benzinga.com/news/events/25/01/42860583/trump-floats-canada-as-51st-us-state-says-hes-ready-to-use-economic-force-to-achieve-it">Canada</a>, <a href="https://www.benzinga.com/startups/25/01/43074027/why-trump-sees-greenland-as-a-2-billion-security-deal">Greenland</a>, and the <a href="https://www.benzinga.com/startups/25/01/43036986/trumps-2-5-billion-power-play-what-seizing-the-panama-canal-would-cost">Panama Canal</a>—suggesting strategic interests that may influence global markets.
While Trump has downplayed the idea of military action, his firm stance on China and Russia suggests economic and strategic priorities will take center stage.
<h2 class="wp-block-heading">The Verdict: Buckle Up For Policy Uncertainty</h2>
Markets prefer certainty, but Trump's second term introduces potential challenges and uncertainties.
JPMorgan's analysts note that Trump's signature &#8220;escalate-to-de-escalate&#8221; strategy could keep investors on edge.
While the stock market benefits from easy financial conditions, Trump&#8217;s return introduces the potential for increased volatility, with tariff increases and geopolitical shifts adding to investor uncertainty.
The iPath Series B S&amp;P 500 VIX Short-Term Futures ETN (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VXX#BATS">VXX</a>) and the ProShares Trust VIX Short-Term Futures ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VIXY#BATS">VIXY</a>) are to funds that seek to profit from volatility.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43156850/wto-chief-says-everyone-will-pay-if-tit-for-tat-trade-war-breaks-out-amid-trumps-tariff-threat-leading-to-double-digit-global-gdp-losses">WTO Chief Says &#8216;Everyone Will Pay&#8217; If &#8216;Tit-For-Tat&#8217; Trade War Breaks Out Amid Trump&#8217;s Tariff Threat, Leading To Double-Digit Global GDP Losses</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Government

Macro Economic Events

Regulations

Politics

Economics

VIXY

Barclays Bank iPath S&P 500 VIX Short-Term Futures ETN

Trump's Second Term Sparks Market Jitters With Trade, Regulation, Expansion Plans

Leerink Partners analyst David Risinger maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and lowers the price target from $182 to $169.

Leerink Partners Maintains Outperform on Johnson & Johnson, Lowers Price Target to $169

JMP Securities analyst Karol Chmiel reiterates RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) from Market Perform to Market Perform.

JMP Securities Reiterates Market Perform on RLIto Market Perform

Michael McCleary, EVP &amp; CFO at Pricesmart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>), disclosed an insider sell on January 22, according to a recent SEC filing.
What Happened: McCleary's decision to sell 4,000 shares of Pricesmart was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001041803/000179671425000002//Archives/edgar/data/1041803/000179671425000002/0001796714-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $358,660.
During Thursday's morning session, Pricesmart shares down by 0.0%, currently priced at $90.64.
<h3>All You Need to Know About Pricesmart</h3>
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
<h3>Unraveling the Financial Story of Pricesmart</h3>
Revenue Growth: Pricesmart's revenue growth over a period of 3 months has been noteworthy. As of 31 August, 2024, the company achieved a revenue growth rate of approximately 9.65%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 17.28%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Pricesmart's EPS is below the industry average. The company faced challenges with a current EPS of 0.95. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Pricesmart's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: Pricesmart's P/E ratio of 19.96 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.54 is lower than the industry average, implying a discounted valuation for Pricesmart's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 9.54, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001041803">Check Out The Full List Of Pricesmart's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

PSMT

Insider Unloading: Michael McCleary Sells $358K Worth Of Pricesmart Shares

Disclosed on January 22, Jack A. Krause, Director at Lovesac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001701758/000162828025002194//Archives/edgar/data/1701758/000162828025002194/0001628280-25-002194-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday outlined that Krause executed a sale of 30,000 shares of Lovesac with a total value of $789,900.
During Thursday's morning session, Lovesac shares down by 0.0%, currently priced at $25.86.
<h3>Get to Know Lovesac Better</h3>
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.
<h3>Financial Milestones: Lovesac's Journey</h3>
Decline in Revenue: Over the 3 months period, Lovesac faced challenges, resulting in a decline of approximately -2.68% in revenue growth as of 31 October, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 58.46%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Lovesac's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -0.32.
</li>
</ul>
Debt Management: Lovesac's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 68.05 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.62 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Lovesac's EV/EBITDA ratio of 25.0 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001701758">Check Out The Full List Of Lovesac's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LOVE

Lovesac Director Sold $789K In Company Stock

JUNS

Jupiter Neurosciences Shares Resume Trading

A substantial insider sell was reported on January 22, by Jacqueline Mutschler, Director at Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>), based on the recent SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001603923/000160392325000035//Archives/edgar/data/1603923/000160392325000035/0001603923-25-000035-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Mutschler sold 887 shares of Weatherford International. The total transaction amounted to $65,629. 
As of Thursday morning, Weatherford International shares are up by 1.25%, currently priced at $71.89.
<h3>Get to Know Weatherford International Better</h3>
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
<h3>Weatherford International: Delving into Financials</h3>
Revenue Growth: Weatherford International displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.31%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 34.92%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Weatherford International's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.117486.
</li>
</ul>
Debt Management: Weatherford International's debt-to-equity ratio is below the industry average. With a ratio of 1.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 9.93, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.96 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 4.94, Weatherford International presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001603923">Check Out The Full List Of Weatherford International's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WFRD

Sell Alert: Jacqueline Mutschler Cashes Out $65K In Weatherford International Stock

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $5.00. Ro...

Arbutus Biopharma: Promising Developments and Positive Outlook Boost Buy Rating

Chardan analyst Keay Nakae raised the firm's price target on Arbutus Biopharma (ABUS) to $5 from $4.50 and keeps a Buy rating on the shares. The fi...

Arbutus Biopharma price target raised to $5 from $4.50 at Chardan

Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) and increased the price target to $5....

Arbutus Biopharma's Promising Clinical Trial Results Lead to Buy Rating

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma, a company specializing in treatments for chronic hepatitis B, is set to partici...

Arbutus Biopharma Highlights Hepatitis B Treatment Advances

Whitefort Capital Management, which is a long-term investor and the third largest shareholder of Arbutus (ABUS) Biopharma with an ownership interes...

Whitefort Capital sends letter to Arbutus Biopharma board of directors

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jefferies says vaccine stocks are higher due to bird flu headlines and the potential downstream revenue implications as investors "hope" for the CO...

Jefferies says Arbutus, Roivant may benefit from bird flu headlines

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

Arbutus expects to significantly reduce its net cash burn in 2025

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), retaining the price target of $5.00. ...

Arbutus Biopharma: Strategic Advancements and Strong Financial Outlook Support Buy Rating

BNTX

CVAC

ROIV

Press Releases

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Present at Jefferies London Healthcare Conference

Biotech

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Comments

Arbutus Biopharma

Arbutus Biopharma (ABUS) 옵션

Arbutus Biopharma (NASDAQ:ABUS) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌